Analysts expect Histogenics Corp (NASDAQ:HSGX) to report ($0.06) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Histogenics’ earnings. Histogenics reported earnings per share of ($0.26) in the same quarter last year, which would suggest a positive year-over-year growth rate of 76.9%. The business is scheduled to report its next earnings report on Thursday, March 21st.
On average, analysts expect that Histogenics will report full year earnings of ($0.24) per share for the current fiscal year. For the next fiscal year, analysts expect that the company will report earnings of ($0.03) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Histogenics.
Get Histogenics alerts:Several equities analysts have recently commented on HSGX shares. Zacks Investment Research raised Histogenics from a “hold” rating to a “buy” rating and set a $0.25 target price on the stock in a research report on Tuesday, January 15th. HC Wainwright set a $1.00 target price on Histogenics and gave the stock a “buy” rating in a research note on Friday, November 9th. Finally, ValuEngine upgraded Histogenics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Histogenics presently has a consensus rating of “Buy” and a consensus target price of $2.44.
In other Histogenics news, major shareholder Randal J. Kirk sold 998,204 shares of the stock in a transaction dated Tuesday, January 15th. The stock was sold at an average price of $0.16, for a total transaction of $159,712.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Randal J. Kirk sold 251,800 shares of the stock in a transaction dated Friday, January 11th. The stock was sold at an average price of $0.17, for a total value of $42,806.00. The disclosure for this sale can be found here. Corporate insiders own 19.70% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC acquired a new stake in shares of Histogenics in the 4th quarter valued at about $25,000. Virtu Financial LLC bought a new position in Histogenics in the 3rd quarter valued at about $117,000. Renaissance Technologies LLC lifted its position in Histogenics by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock valued at $961,000 after acquiring an additional 22,133 shares in the last quarter. Finally, BlackRock Inc. lifted its position in Histogenics by 72.0% in the 2nd quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 22,927 shares in the last quarter. Institutional investors own 17.04% of the company’s stock.
NASDAQ HSGX remained flat at $$0.13 during trading on Wednesday. The company’s stock had a trading volume of 6,144,066 shares, compared to its average volume of 12,962,290. The firm has a market capitalization of $8.13 million, a P/E ratio of -0.14 and a beta of 3.71. Histogenics has a 1 year low of $0.08 and a 1 year high of $3.35.
About Histogenics
Histogenics Corp. engages in the development, marketing, and commercialization of musculoskeletal medicine. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually and in concert to treat musculoskeletal-related conditions.
Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers
Get a free copy of the Zacks research report on Histogenics (HSGX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment